Male pattern baldness affects about half of all men by age 50. Women lose hair too, but far less dramatically and far less often. The reason comes down to a single hormone, a gene located on the X chromosome, and the peculiar way human hair follicles respond to both.
The Hormone: DHT
The culprit is dihydrotestosterone, or DHT. Your body makes it from testosterone using an enzyme called 5-alpha reductaseAn enzyme that converts testosterone into dihydrotestosterone (DHT), making it central to the hormonal pathway responsible for male pattern baldness; the target of the drug finasteride.. Men produce far more testosterone than women, which means they also produce far more DHT. That matters because DHT binds to receptors in hair follicles on the scalp and, over time, shrinks them. The follicles don’t die immediately. They miniaturize: each growth cycle produces a thinner, shorter, lighter hair until eventually the follicle produces nothing visible at all.
The evidence that DHT is the driver is unusually clean. Men born with a genetic condition called 5-alpha reductase deficiency, whose bodies cannot convert testosterone into DHT, do not go bald. Neither do people with androgen insensitivity syndrome, whose cells cannot respond to androgens at all. Remove DHT from the equation, and male pattern baldness simply does not happen.
The Gene Behind Male Pattern Baldness
DHT alone does not explain why some men go bald at 25 and others keep a full head of hair into their 70s. The difference is genetic, and the most important gene sits on the X chromosome.
The androgen receptor gene (AR) determines how sensitive your hair follicles are to DHT. Certain variants of this gene produce receptors that are more easily stimulated by androgens than normal, leading to increased receptor activity in follicles. A 2005 study published in the American Journal of Human Genetics found that variation in the AR gene has an etiological fraction of 0.46 for early-onset baldness, meaning it accounts for roughly 46% of the genetic risk.
Here is where the inheritance gets interesting. Men have one X chromosome, inherited from their mother. If your mother carries a high-sensitivity AR variant on one of her X chromosomes, you have a coin-flip chance of inheriting it. This is why the old saying that baldness comes from your mother’s side has a grain of truth, though it is not the whole story. Twin studies suggest heredity accounts for approximately 80% of predisposition to androgenetic alopeciaThe medical term for hormone-related pattern hair loss, caused by genetic sensitivity of hair follicles to androgens like DHT; the most common form of baldness in men and women., and genome-wide studies have identified over 70 associated genetic loci across multiple chromosomes, not just the X.
Why Women Are (Mostly) Protected
Women have two X chromosomes. If one carries a high-sensitivity AR variant, the other may carry a normal version, diluting the effect. Women also produce far less testosterone (and therefore far less DHT) than men. This double protection, genetic and hormonal, is why female pattern hair loss follows a different trajectory: thinning across the top of the scalp rather than the receding hairline and crown loss typical in men, and rarely progressing to total baldness.
After menopause, when estrogen levels drop and the relative influence of androgens increases, women become more susceptible. This is consistent with the hormonal model: the less estrogen there is to counterbalance androgens, the more follicle miniaturization can occur.
The Paradox Nobody Explains Well
One genuinely strange aspect of DHT and hair: the same hormone that kills follicles on your scalp is the one that grows your beard, chest hair, and body hair during puberty. Scalp follicles and body follicles respond to DHT in opposite ways, and the mechanism behind this is still not fully understood. The leading hypothesis involves differences in how dermal papillaA cluster of specialized cells at the base of a hair follicle that controls its growth cycle; the primary site where DHT signaling triggers follicle miniaturization in androgenetic alopecia. cells in different body regions interpret androgen signaling, but the field has not nailed down a complete explanation. If someone tells you they have this fully figured out, they are selling something.
Male Pattern Baldness in Numbers
Androgenetic alopecia affects an estimated 50 million men and 30 million women in the United States. Among Caucasian men, roughly 50% show noticeable hair loss by age 50, rising to around 80% by age 70. The condition is less prevalent and tends to appear later in men of East Asian and African descent. In women, noticeable thinning typically begins after menopause.
Healthy hair spends most of its life in the growth phase (anagenThe active growth phase of a hair follicle, during which the hair shaft is produced; it typically lasts two to seven years and accounts for most scalp hairs at any given time.), with a normal anagen-to-resting ratio of about 12:1. In people with androgenetic alopecia, this ratio drops to around 5:1, meaning follicles spend proportionally far more time resting and far less time growing.
What Can Be Done About It
Two treatments have strong clinical evidence. Minoxidil (the active ingredient in Rogaine) is a topical treatment that extends the growth phase of follicles. It does not block DHT but appears to increase blood flow and potassium channel activity in follicles. Finasteride (Propecia) blocks the type 2 5-alpha reductase enzyme and reduces scalp DHT by about 64%. Both require continuous use; stop taking them, and the hair loss resumes.
Neither is a cure. Both are more effective at slowing loss and maintaining existing hair than at regrowing what is already gone. Hair transplant surgery physically relocates DHT-resistant follicles from the back of the scalp to affected areas, which is why transplanted hair persists: those follicles never had the receptor sensitivity that killed their neighbors. Male pattern baldness is treatable but, as of now, not reversible.
Androgenetic alopeciaThe medical term for hormone-related pattern hair loss, caused by genetic sensitivity of hair follicles to androgens like DHT; the most common form of baldness in men and women. (AGA), commonly known as male pattern baldness, is a polygenicDescribes a trait or disease influenced by many genes, each contributing a small effect. Most common diseases like diabetes and heart disease are polygenic., androgen-dependent condition affecting approximately 50% of males by age 50 and a significant but lower proportion of females, typically post-menopause. The molecular mechanism centers on dihydrotestosterone (DHT) acting through androgen receptors in the dermal papillaA cluster of specialized cells at the base of a hair follicle that controls its growth cycle; the primary site where DHT signaling triggers follicle miniaturization in androgenetic alopecia. of susceptible hair follicles, but the full genetic architecture involves dozens of loci beyond the canonical androgen receptor gene.
DHT and the 5-Alpha ReductaseAn enzyme that converts testosterone into dihydrotestosterone (DHT), making it central to the hormonal pathway responsible for male pattern baldness; the target of the drug finasteride. Pathway
Testosterone is converted to DHT by the enzyme 5-alpha reductase. Two isoforms are relevant: type 1 (found in sebaceous glands and epidermis) and type 2 (found in dermal papilla and inner root sheath of hair follicles). Type 2 accounts for approximately 80% of circulating DHT and is the primary target of finasteride. DHT binds the androgen receptor with approximately 5 times the avidity of testosterone, making it the more potent downstream effector.
The clinical proof that DHT is necessary for AGA comes from two natural experiments. Individuals with 5-alpha reductase type 2 deficiency, who cannot convert testosterone to DHT efficiently, do not develop androgenetic alopecia. Similarly, individuals with complete androgen insensitivity syndrome (non-functional androgen receptors) retain a full head of hair. These observations establish that the androgen receptor pathway, specifically DHT-mediated activation, is necessary for follicular miniaturization.
At the follicle level, sustained DHT signaling shortens the anagenThe active growth phase of a hair follicle, during which the hair shaft is produced; it typically lasts two to seven years and accounts for most scalp hairs at any given time. (growth) phase and prolongs the telogen (resting) phase. In healthy scalps, the anagen-to-telogen ratio is approximately 12:1; in AGA-affected scalps, this drops to approximately 5:1. Over successive cycles, terminal hairs are progressively replaced by vellus-like miniaturized hairs until the follicle produces no cosmetically significant fiber.
Genetic Architecture of Male Pattern Baldness
The androgen receptor gene (AR), located at Xq12, is the single largest genetic determinant of early-onset AGA. Hillmer et al. (2005) demonstrated that variation in AR has an etiological fraction of 0.46 for early-onset AGA, identifying a polyglycine-encoding GGN repeat in exon 1 as the likely functional variant. The X-chromosomal location of AR means males inherit it exclusively from their mothers, which is consistent with the well-documented maternal inheritance signal in baldness.
However, AR alone does not account for the full heritabilityA statistical measure of how much variation in a trait within a population is explained by genetic differences. A heritability of 50% means genes account for half the variation in risk.. Twin studies estimate that genetic factors explain approximately 80% of AGA predisposition. A large-scale GWAS meta-analysis identified 71 significantly associated loci, 30 previously undescribed, which collectively account for about 38% of heritability. Variance partitioning suggests that autosomal SNPs explain a larger proportion of genetic liability than X-chromosome SNPs, confirming that AGA is genuinely polygenic and not simply an X-linked trait.
Sons of affected fathers have a 5 to 6 times higher relative risk of developing AGA. Since fathers do not contribute an X chromosome to sons, this paternal signal must come from autosomal loci, further evidence that the “blame your mother” model, while partially correct, is incomplete.
Sex Differences in Susceptibility
The sex disparity in AGA results from at least three interacting factors. First, circulating testosterone (and therefore DHT) is substantially higher in males. Second, the XX karyotype in females means a deleterious AR variant on one X chromosome may be compensated by a normal allele on the other, though X-inactivation makes this more probabilistic than deterministic. Third, estrogens appear to have a direct protective effect on hair follicles, potentially through aromatase activity in the follicle converting testosterone to estradiol rather than allowing its conversion to DHT.
This hormonal model predicts that female AGA should increase after menopause, which is precisely what the epidemiological data show. The pattern of loss also differs: females typically present with diffuse thinning across the crown with preservation of the frontal hairline (Ludwig pattern), while males show the familiar bitemporal recession and vertex thinning (Hamilton-Norwood pattern).
The DHT Paradox
One unresolved question in androgen biology is why DHT promotes hair growth in some regions (beard, axillary, pubic) while inducing miniaturization in scalp follicles. Dermal papilla cells from different body sites appear to have distinct transcriptomic profiles and respond to androgen receptor activation with different downstream gene expression programs. Some evidence implicates Wnt/beta-catenin signaling as a potential mediator, with DHT suppressing Wnt in scalp follicles while promoting it in beard follicles. The precise molecular switch remains an active area of research.
Pharmacological Intervention
Finasteride (1 mg/day) is a selective type 2 5-alpha reductase inhibitor that reduces scalp DHT levels by approximately 64%. It is most effective at the vertex and less effective at the temporal regions. Dutasteride, a dual type 1/type 2 inhibitor, achieves greater DHT suppression but is not FDA-approved for AGA in most jurisdictions. Minoxidil (topical, 2-5%) acts through a mechanism independent of the androgen pathway, likely involving potassium channel opening and increased follicular blood flow. Combined therapy with both agents generally produces more favorable outcomes than monotherapy.
Finasteride is contraindicated in women of reproductive age due to the risk of feminization of male fetuses. This therapeutic constraint is itself informative: it underscores how central DHT is to male sexual development and why interfering with it requires caution.
This article is for informational purposes only and does not constitute medical advice. If you are experiencing hair loss, consult a qualified healthcare provider for personalized evaluation and treatment options.
